Balyasny Asset Management
DSGN icon

Balyasny Asset Management’s Design Therapeutics DSGN Stock Holding History

Balyasny Asset Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,499
Closed -$117K – 2359
2023
Q2 		$117K Buy
+18,499
New +$113K ﹤0.01% 2110
2022
Q4 		– Sell
-11,134
Closed -$186K – 2877
2022
Q3 		$186K Buy
+11,134
New +$222K ﹤0.01% 2321
2021
Q2 		– Sell
-43,250
Closed -$1.29M – 2048
2021
Q1 		$1.29M Buy
+43,250
New +$1.46M 0.01% 1167

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management's DSGN Position: Q3 2023 in Review

Balyasny Asset Management sold out of Design Therapeutics (DSGN) in Q3 2023, closing a stake of 18,499 shares — an estimated $117K sold.

Balyasny Asset Management first reported a position in DSGN in Q1 2021 and held it in 3 quarters. The position peaked at $1.29M in Q1 2021. 87 funds tracked by Wall St. Rank hold DSGN as of Q3 2023.

  • Balyasny Asset Management reported no remaining Design Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 18,499 Design Therapeutics shares in Q3 2023, an estimated $117K.
  • Balyasny Asset Management first reported a position in Design Therapeutics in Q1 2021 and held it in 3 quarters.
  • Balyasny Asset Management's Design Therapeutics position peaked at $1.29M in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2023.

Based on Balyasny Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.